Erslev A J
Cardeza Foundation, Thomas Jefferson University, Philadelphia, PA 19107.
Leuk Res. 1990;14(8):683-8. doi: 10.1016/0145-2126(90)90094-p.
The remarkable capacity of the bone marrow to compensate for blood loss and for reduced atmospheric oxygen tension has been found to be mediated by a renal hormone, named erythropoietin. It is produced by peritubular interstitial cells in response to renal hypoxia, but molecular engineering has permitted large scale production of an identical recombinant erythropoietin in vitro. When used as a replacement hormone in patients with impaired endogenous production it has been found to be capable of improving or eliminating the anemia of chronic kidney disease and the anemia of prematurity. In the future it may also be used as a pharmacologic agent and possibly be able to control the anemia of patients with bone marrow failure and make them transfusion-independent.
骨髓具有显著的能力来补偿失血和应对降低的大气氧张力，现已发现这种能力是由一种名为促红细胞生成素的肾激素介导的。它由肾小管周围间质细胞在肾缺氧时产生，但分子工程已能在体外大规模生产相同的重组促红细胞生成素。当作为内源性生成受损患者的替代激素使用时，已发现它能够改善或消除慢性肾病贫血和早产儿贫血。未来它还可能用作一种药物制剂，或许能够控制骨髓衰竭患者的贫血并使其无需输血。
